Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US

Juday, Timothy; Correll, Todd; Anene, Ayanna; Broder, Michael S.; Ortendahl, Jesse; Bentley, Tanya
September 2013
ClinicoEconomics & Outcomes Research;2013, Vol. 5, p437
Academic Journal
Background: February 2013 US treatment guidelines recommend the once-daily tablet of efavirenz/emtricitabine/tenofovir (Atripla®) as a preferred regimen and the once-daily tablet of elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild™) as an alternative regimen for first-line treatment of human immunodeficiency virus (HIV). This study assessed the clinical and economic trade-offs involved in using Atripla compared with Stribild as first-line antiretroviral therapy in HIV-infected US adults. Methods: A Markov cohort model was developed to project lifetime health-related outcomes, costs, quality-adjusted life years (QALYs), and cost-effectiveness of Stribild compared with Atripla as first-line antiretroviral therapy in HIV-1-infected US patients. Patients progressed in 12-week cycles through second-line, third-line, and nonsuppressive therapies, acquired immune deficiency syndrome, and death. Baseline characteristics and first-line virologic suppression, change in CD4 count, and adverse effects (lipid, central nervous system, rash, renal) were based on 48-week clinical trial results. These results demonstrated equivalent virologic suppression between the two regimens. Point estimates for virologic suppression (favoring Stribild) were used in the base case, and equivalency was used in the scenario analysis. Published sources and expert opinion were used to estimate costs, utilities, risk of acquired immune deficiency syndrome, mortality, subsequent-line CD4 count, clinical efficacy, and adverse events. Costs were reported in 2012 US dollars. Sensitivity analyses were conducted to assess robustness of results. Results: Compared with patients initiating Atripla, patients initiating Stribild were estimated to have higher lifetime costs. Stribild added 0.041 QALYs over a lifetime at an additional cost of $6,886, producing an incremental cost-effectiveness ratio of $166,287/QALY gained. Results were most sensitive to first-line response rates, product costs, and likelihood of renal adverse events. When equivalent efficacy was assumed, Atripla dominated Stribild with lower costs and greater QALYs. Conclusion: At a societal willingness to pay of $100,000/QALY, Stribild was not cost-effective in the base case compared with Atripla for first-line HIV treatment.


Related Articles

  • Plasma concentrations of efavirenz are associated with body weight in HIV-positive individuals. Poeta, Julia; Linden, Rafael; Antunes, Marina Venzon; Real, Lucia; Menezes, Andréia Magalhães; Ribeiro, Jorge P.; Sprinz, Eduardo // Journal of Antimicrobial Chemotherapy (JAC);Nov2011, Vol. 66 Issue 11, p2601 

    Background Efavirenz is among the most widely used antiretroviral drugs. Increased efavirenz exposure has been associated with CNS side effects and also with the chance of emergence of resistance upon treatment interruptions. The objective of this study was to evaluate factors associated with...

  • Long-term Treatment With Raltegravir or Efavirenz Combined With Tenofovir/ Emtricitabine for Treatment-Naive Human Immunodeficiency Virus-1-Infected Patients: 156-Week Results From STARTMRK. 6Rockstroh, Jürgen K.; Lennox, Jeffrey L.; De Jesus, Edwin; Saag, Michael S.; Lazzarin, Adriano; Wan, Hong; Walker, Monica L.; Xu, Xia; Zhao, Jing; Teppler, Hedy; DiNubile, Mark J.; Rodgers, Anthony J.; Nguyen, Bach-Yen; Leavitt, Randi; Sklar, Peter // Clinical Infectious Diseases;10/15/2011, Vol. 53 Issue 8, p807 

    Background. We compared 3 years of antiretroviral therapy with raltegravir or efavirenz as part of a combination regimen in the ongoing STARTMRK study of treatment-naive patients infected with human immunodeficiency virus (HIV). Methods. Eligible patients with HIV-1 RNA (vRNA) levels >5000...

  • 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. Porter, Danielle P.; Kulkarni, Rima; Fralich, Todd; Miller, Michael D.; White, Kirsten L. // HIV Clinical Trials;02/01/2015, p30 

    Background: STaR (GS-US-264-0110) was a 96-week phase 3b study evaluating the safety and efficacy of two single-tablet regimens, rilpivirine/emtricitabine/tenofovir DF (RPV/FTC/TDF) and efavirenz/emtricitabine/tenofovir DF (EFV/FTC/TDF) in treatment-naive, HIV-1-infected subjects. Methods:...

  • Searching for `best value' first-line HIV antiretrovirals.  // PharmacoEconomics & Outcomes News;6/15/2013, Issue 680, p10 

    The article discusses studies which examined the cost effectiveness of antiretroviral agents in patients with HIV infections. One study compared the costs and outcomes of efavirenz with generic nevirapine using a micro-stimulation model. Another research assessed once-daily...

  • Use of Non-Nucleoside Analogues Together with Rifampin in HIV Patients with Tuberculosis. Villar, J.; Sánchez, P.; González, A.; Sorli, L; Montero, M.M.; Guelar, A.; Solé, E.; López, J. L.; Knobel, H. // HIV Clinical Trials;May/Jun2011, Vol. 12 Issue 3, p171 

    Objective: The concomitant use of rifampin (RFP) with efavirenz (EFV) or nevirapine (NVP) is frequent in HIV patients with tuberculosis (TB). The necessity of increasing the dose of EFV remains controversial. The aim of the study was to evaluate the outcome of HIV infection in patients treated...

  • Minimum effective plasma concentration of efavirenz in treatment-naïve Chinese HIV-infected patients. Sun, J.; Chen, J.; Yao, Y.; Zhang, R.; Zheng, Y.; Liu, L.; Zhang, L.; Shen, Y.; Lu, H. // International Journal of STD & AIDS;Dec2010, Vol. 21 Issue 12, p810 

    To assess the relationship between mean efavirenz (EFV) plasma concentration and clinical effect during the first 48 weeks of combination antiretroviral therapy (cART), the baseline CD4 cell count was recorded and plasma EFV concentration and CD4 cell count were measured every 12 weeks. HIV-RNA...

  • Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial). Gallien, Sébastien; Journot, Valérie; Rozenbaum, Willy; Yéni, Patrick; Morlat, Philippe; Poizot-Martin, Isabelle; Reynes, Jacques; Reliquet, Véronique; Leclercq, Pascale; Simon, François; Chêne, Geneviève; Molina, Jean-Michel // Journal of Antimicrobial Chemotherapy (JAC);Jan2011, Vol. 66 Issue 1, p184 

    Background Once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine. Methods The ALIZE ANRS 099 trial enrolled 355 adults with...

  • Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis. Ngaimisi, E.; Mugusi, S.; Minzi, O.; Sasi, P.; Riedel, K.-D.; Suda, A.; Ueda, N.; Janabi, M.; Mugusi, F.; Haefeli, W. E.; Bertilsson, L.; Burhenne, J.; Aklillu, E. // Clinical Pharmacology & Therapeutics;Sep2011, Vol. 90 Issue 3, p406 

    We performed a prospective comparative study to examine, from a pharmacogenetics perspective, the effect of rifampicin (RIF) on long-term efavirenz (EFV) autoinduction and kinetics. In a study population of patients with HIV receiving EFV with RIF (arm 2, n = 54) or without RIF (arm 1, n = 128...

  • Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. Wyen, Christoph; Hendra, Heidy; Siccardi, Marco; Platten, Martin; Jaeger, Hans; Harrer, Thomas; Esser, Stefan; Bogner, Johannes R.; Brockmeyer, Norbert H.; Bieniek, Bernhard; Rockstroh, Juergen; Hoffmann, Christian; Stoehr, Albrecht; Michalik, Claudia; Dlugay, Verena; Jetter, Alexander; Knechten, Heribert; Klinker, Hartwig; Skaletz-Rorowski, Adriane; Fätkenheuer, Gerd // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p2092 

    Objectives Cytochrome P450 2B6 (CYP2B6) is responsible for the metabolic clearance of efavirenz and single nucleotide polymorphisms (SNPs) in the CYP2B6 gene are associated with efavirenz pharmacokinetics. Since the constitutive androstane receptor (CAR) and the pregnane X receptor (PXR)...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics